The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. Pfizer and ...
Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA ...
BioNTech SE (NASDAQ:BNTX) on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents. The COVID-19 ...
BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. The recent acquisition of CureVac and the deal with Bristol Myers Squibb validate ...
BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion. The announcement makes no specific mention of onboarding ...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results